Bruker (NASDAQ:BRKR) Stock

BRUKER CORP

Bruker

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.

It hardly seems possible that we have already covered six months of 2025. Of course at times it has seemed like 2025 has already lasted a decade.
This week I want to take a look at large C-Suite purchases that happened in the first six months of the year that have not yet delivered the hoped for gains. These stocks are trading at several times below their purchase price and may represent opportunities for patient investors willing to follow management&#8217;s lead.
Petco Health and Wellness Company (Ticker: WOOF) Petco is a category defining health and wellness company focused on improving the lives of pets, pet parents and partners. They operate more than 1,500 pet care centers across the U.S., Mexico, and Puerto Rico. For fiscal 2024, the company reported net revenue of $6.1 billion, down 2.2% year over year, with a net loss of $101.8 million compared to a $1.3 billion loss in 2023. That previous year loss included a $1.2 billion goodwill impairment charge, so the underlying business actually improved significantly.
The business model encompasses retail stores, services, e-commerce, and veterinary care across comprehensive pet wellness categories. Management expects double digit Adjusted EBITDA growth in 2025 and has reaffirmed its fiscal 2025 outlook despite incorporating tariff impacts. The company generated positive free cash flow of $49.7 million in 2024 compared to negative $9.9 million in 2023, demonstrating improved cash generation.
The pet industry&#8217;s defensive characteristics and ongoing premiumization trends support long term growth, though margin pressure from competitive dynamics and supply chain costs remain challenges. The company&#8217;s focus on health and wellness services provides differentiation opportunities.
Back in March CEO Joel Anderson bought $4.7 million worth of stock at around $3 a share. Clearly he is not looking for a few percentage points but is hoping that the stock regains some lost ground and becomes a five bagger or better for patient aggressive investors.
Bruker Corporation (Ticker: BRKR) Bruker drives profitable growth by enabling scientific discoveries and delivering high performance analytical, life science and diagnostic solutions as a market leader in high value analytical technologies. In 2024, Bruker&#8217;s revenue was $3.37 billion, an increase of 13.56% compared to the previous year&#8217;s $2.96 billion. The company holds over 1,200 patents globally and generated approximately $150 million in revenue from licensing in 2023, while allocating around 10% of annual revenue to R&amp;D.
Bruker reported preliminary Q1 2025 revenue of $795 to $800 million, implying approximately 10% year over year growth with low double digit constant currency growth. The company has consistently delivered above market organic revenue growth and double digit constant currency revenue growth, demonstrating the success of its Project Accelerate transformation.
Growth drivers include expansion in life sciences applications, particularly in proteomics and spatial biology, plus strong positioning in semiconductor metrology for AI applications. The company&#8217;s recurring service revenue and installed base provide stability, while innovation investments support premium pricing power.
CEO Frank Laukien has spent over $1.1 million so far this year buying stock in the open market. The stock is trading at about half of the 2024 highs, and it is clear the guy in charge thinks the shares can get back to there and beyond.
Heartland Express (Ticker: HTLD) Heartland Express operates as a short, medium, and long haul truckload carrier and transportation services provider in the United States, Mexico, and Canada. The company reported Q1 2025 operating revenues of $219.4 million compared to $270.3 million in Q1 2024, with a net loss of $13.9 million. For full year 2024, operating revenue was $1.0 billion with a net loss of $29.7 million. As of 2024, Heartland Express operates a fleet of 1,890 tractors and 6,100 trailers with 14 strategic terminal locations.
CEO Mike Gerdin noted a &#8220;positive shift in customer rate and volume negotiations that we expect to strengthen as the year unfolds&#8221; despite ongoing freight market challenges. The global cold chain logistics market is projected to reach $340.3 billion by 2025 with a 9.6% compound annual growth rate, providing opportunities for Heartland&#8217;s specialized refrigerated transportation capabilities.
However, the company faces headwinds from elevated fuel costs, driver shortages, and cyclical freight market weakness. Recovery potential exists as freight markets normalize, and the company&#8217;s operational improvements gain traction.
Gerdin has backed up his optimism with cash as he has spent more than $2.4 million so far buying shares of Heartland this year.
Tidewater (Ticker: TDW) Tidewater owns and operates one of the largest fleets of offshore support vessels in the industry, with over 60 years of experience supporting offshore energy exploration and production activities worldwide. For 2024, Tidewater reported record revenue of $1.35 billion, up 33% from 2023, with net income of $180.7 million nearly doubling from $97.2 million in 2023. The average day rate increased 26.6% to $21,273 per day with Adjusted EBITDA growing 44.7% to $559.6 million.
Management provided 2025 revenue guidance of $1.32 to $1.38 billion with gross margin guidance of 48% to 50%, expecting similar or slightly better performance than 2024. According to management, &#8220;The offshore vessel supply situation remains favorable, with limited newbuilds on order and no deliveries expected in 2025.&#8221; The supply demand imbalance in offshore vessels supports continued rate improvements. Energy transition investments in offshore wind also present growth opportunities. Key risks include oil price volatility, regulatory changes, and potential new vessel capacity additions.
In December CEO Quintin Kneen spent $2 million buying shares. Noted value investor and board member Robert Robotti has spent over $2 million on stock this year as well.
Amcor (Ticker: AMCR) Amcor develops, produces, and sells packaging products globally, operating in two segments: Flexibles and Rigid Packaging across food and beverage, medical and pharmaceutical, fresh produce, and personal care industries. In fiscal 2024, 41,000 Amcor people generated $13.6 billion in annual sales from operations spanning 212 locations in 40 countries. Net sales of $13.64 billion were 7% lower than the previous year, reflecting approximately 5% lower volumes and unfavorable price/mix impact.
Amcor is committed to 100% recyclable or reusable packaging by 2025, currently at 95.7%, and 30% recycled content by 2030, positioning the company well for sustainability driven demand. The company&#8217;s focus on innovation, sustainability leadership, and customer centricity provides competitive advantages in premiumization trends. Growth drivers include e-commerce packaging demand, healthcare packaging expansion, and sustainable packaging solutions. Challenges include raw material cost volatility, competitive pricing pressure, and economic sensitivity affecting packaging demand.
CEO Peter Konieczny has invested an additional $1 million in Amcor shares so far in 2025 at higher prices.
Arbor Realty Trust (Ticker: ABR) Arbor Realty Trust is a nationwide real estate investment trust and direct lender providing loan origination and servicing for multifamily, single family rental portfolios, and other diverse commercial real estate assets. For 2024, the company reported distributable earnings of $1.74 per share with a return on equity of approximately 14%. The servicing portfolio grew 8% year over year to $33.5 billion. As of Q1 2025, the company&#8217;s loan and investment portfolio averaged $11.39 billion with a weighted average yield of 8.15%.
Management expects distributable earnings of $0.30 to $0.35 per quarter in 2025, down from $0.40 in Q4 2024, reflecting elevated interest rate challenges. The company closed a $1.15 billion repurchase facility with JPMorgan, generating approximately $80 million in additional liquidity. Single family rental business achieved $1.7 billion in new loans in 2024, surpassing previous year production.
Growth potential exists in the expanding single family rental market and eventual interest rate normalization, though near term earnings face pressure from real estate owned repositioning costs and elevated funding costs.
CEO Ivan Kaufman has spent about $2 million buying stock this year and several other officers and directors have also been buying stock in hopes of a multi-bagger rebound.
VF Corporation (Ticker: VFC) VF Corporation is a portfolio of leading outdoor, active and workwear brands, including The North Face, Vans, Timberland, and Dickies. The company completed the sale of Supreme brand on October 1, 2024, and used proceeds to pay down its $1 billion term loan. VF operates through a diversified portfolio strategy spanning outdoor recreation, lifestyle footwear, and workwear categories with global reach across multiple distribution channels.
Management noted &#8220;sequential and broad based improvement in year on year trends&#8221; with progress on four Reinvent priorities and tracking toward $300 million savings target by end of fiscal year 2025. The company is implementing transformation program &#8220;Reinvent&#8221; to build new capabilities and leverage its brand portfolio for sustainable profitable growth. Recovery potential exists through brand repositioning, operational efficiency improvements, and market share gains in outdoor/active categories. However, challenges include Vans brand struggles.
CEO Bracken Darell has purchased over $1 million of stock recently and CFO Abhishek Dalmia spent almost $600,000 buying additional shares as well.
The Bottom Line When CEOs and other insiders are putting their own money where their mouth is, it&#8217;s worth paying attention. These seven companies represent different sectors and different challenges, but they all have one thing in common: management believes strongly enough in the turnaround story to risk significant personal capital. Of course, insider buying doesn&#8217;t guarantee success. Management can be wrong about their own companies. But it does provide a useful screen for finding potential opportunities where the people who know the business best are betting on recovery. For patient investors willing to do their homework and accept the risks, these conviction plays may offer the potential for outsized returns as these businesses work through their current challenges.

Opinion

AMCR

BRKR

HTLD

WOOF

Alpha Buying: When Leadership Buys, Should You Follow?

9 analysts have shared their evaluations of Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $48.22, a high estimate of $60.00, and a low estimate of $40.00. A decline of 18.88% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1750960850_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Bruker. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$46.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$48.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Bruker. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Bruker compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Bruker's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Bruker's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BRKR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bruker analyst ratings.</a>
<h2>All You Need to Know About Bruker</h2>
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
<h3>Financial Milestones: Bruker's Journey</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Bruker showcased positive performance, achieving a revenue growth rate of 11.04% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 2.17%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Bruker's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.97%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Bruker's ROA stands out, surpassing industry averages. With an impressive ROA of 0.3%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Bruker's debt-to-equity ratio stands notably higher than the industry average, reaching 1.16. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

A Glimpse Into The Expert Outlook On Bruker Through 9 Analysts

B of A Securities analyst Derik De Bruin maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Buy and lowers the price target from $61 to $50.

News

Price Target

B of A Securities Maintains Buy on Bruker, Lowers Price Target to $50

<a href="https://www.statnews.com/2025/06/25/nih-halts-research-grant-terminations-email-shows/?utm_campaign=twitter_organic&amp;utm_medium=social&amp;utm_source=twitter">https://www.statnews.com/2025/06/25/nih-halts-research-grant-terminations-email-shows/?utm_campaign=twitter_organic&amp;utm_medium=social&amp;utm_source=twitter</a>

General

ILMN

QTRX

'NIH halts grant terminations 'effective immediately,' email says'- Stat News

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com&amp;esheet=54281322&amp;newsitemid=20250624897472&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=b0fc39e8bddd039ed3dffd2263493101">Bruker Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) today announced the shipment and installation of the 15th InSight WLI 3D optical metrology system to a leading semiconductor manufacturer. The installation is part of a larger order from this semiconductor manufacturer for 27 Bruker optical metrology systems in 2025. This reflects the growing demand for high-performance metrology that can support advanced packaging requirements in the latest generation AI high-performance chip manufacturing processes.

Bruker Ships 15th High-Tech Metrology System as AI Chip Demand Fuels Surge in Semiconductor Tools

Health Care

Bruker Acquires Biocrates Life Sciences Ag, Located In Innsbruck, Austria. Financial Terms Were Not Disclosed

A. New proteoElute nanoflow nLC system features ceramic valves, proteoTrap trapping columns, and TwinScape-enabled predictive maintenance technology
B. Introducing new generation of PepSep Advanced nLC columns to further improve chromatographic resolution, sensitivity and proteomics identifications
At the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com%2F&amp;esheet=54263257&amp;newsitemid=20250602715993&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=17d2f94ec69b3f1e87b36b18a38df92a">Bruker Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) today announced the new proteoElute nanoLC system, featuring ceramic valves, proteoTrap trapping columns, and next-generation PepSep Advanced nLC columns, further enhancing robustness, sensitivity and proteome coverage in ultra-sensitive proteomics workflows.

Bruker Launches proteoElute nanoLC System, Advancing Ultra-Sensitive Proteomics

Breakthrough Athena Ion Processor (AIP) delivers up to 35% more peptide and 20% more protein identifications for highest sensitivity proteomics
At the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com%2F&amp;esheet=54263258&amp;newsitemid=20250602810313&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=7ec8a18c42acb3ef4e62e11c4e05f4ab">Bruker Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) today announced significant further advances in ultra-high sensitivity 4D-Proteomics&#x2122; with the introduction of the timsUltra AIP mass spectrometer. Its innovative, breakthrough Athena Ion Processor (AIP) technology further boosts the extreme sensitivity of timsTOF Ultra PASEF&#xAE; methods for key biological and clinical research problems with very low sample amounts.

Bruker Unveils New timsUltra AIP System With Enhanced, Extreme Sensitivity for Single-Cell Proteomics, FNA Biopsy Immunopeptidomics And Metaproteomics

Bruker Unveils timsMetabo Mass Spectrometer With Advanced TIMS 'MoRE' Scan-Mode

Analysts' ratings for Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) over the last quarter vary from bullish to bearish, as provided by 8 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Bruker, revealing an average target of $48.0, a high estimate of $60.00, and a low estimate of $40.00. This current average has decreased by 18.99% from the previous average price target of $59.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1747918856_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Bruker among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$46.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$48.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$60.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bruker. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bruker compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Bruker's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Bruker's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BRKR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bruker analyst ratings.</a>
<h2>Delving into Bruker's Background</h2>
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
<h3>Bruker: Financial Performance Dissected</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Bruker's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 11.04%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Bruker's net margin is impressive, surpassing industry averages. With a net margin of 2.17%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Bruker's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.97%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.3%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Bruker's debt-to-equity ratio surpasses industry norms, standing at 1.16. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Bruker Through The Eyes Of 8 Analysts

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>HC Wainwright &amp; Co. analyst Raghuram Selvaraju downgraded the rating for UroGen Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) from Buy to Neutral. UroGen Pharma shares closed at $4.17 on Wednesday. <a href="https://www.benzinga.com/quote/URGN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson analyst Peter Heckmann downgraded Guidewire Software, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) from Buy to Neutral and announced a $226 price target. Guidewire Software shares closed at $210.84 on Wednesday. <a href="https://www.benzinga.com/quote/GWRE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Lydia Rainforth downgraded the rating for Equinor ASA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQNR#NYSE">EQNR</a>) from Overweight to Equal-Weight. Equinor shares closed at $23.62 on Wednesday. <a href="https://www.benzinga.com/quote/EQNR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wedbush analyst Laura Chico downgraded Vigil Neuroscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) from Outperform to Neutral and lowered the price target from $13 to $8. Vigil Neuroscience shares closed at $2.31 on Wednesday. <a href="https://www.benzinga.com/quote/VIGL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Patrick Donnelly downgraded Bruker Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) from Buy to Neutral and cut the price target from $50 to $40. Bruker shares closed at $36.45 on Wednesday. <a href="https://www.benzinga.com/quote/brkr/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying GWRE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="607" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22075148/image-284-1024x607.png" alt="" class="wp-image-924250" style="width:676px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22075148/image-284-1024x607.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22075148/image-284-300x178.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22075148/image-284-768x455.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/22075148/image-284.png 1125w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45540545/jim-cramer-recommends-not-buying-mosaic-doesnt-like-this-industrial-stock">Jim Cramer Recommends Not Buying Mosaic, Doesn&#8217;t Like This Industrial Stock</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Pre-Market Outlook

Markets

Trading Ideas

EQNR

GWRE

URGN

VIGL

This Guidewire Software Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

Citigroup analyst Patrick Donnelly downgrades Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) from Buy to Neutral and lowers the price target from $50 to $40.

Citigroup Downgrades Bruker to Neutral, Lowers Price Target to $40

Legal

10x Genomics Reaches Patent Litigation Settlement With Bruker; Bruker To Pay $68M In Equal Quarterly Installments Between Q3 2025 And Q2 2026 As Well As Ongoing Royalties On Sales Of Spatial Biology Products Through Life Of Licensed Patents

Bruker And 10x Genomics Settle Patent Disputes And Enter Global Cross-License Agreement, Dismissing All Ongoing Litigations

The Federal Circuit rejects Bruker Cellular's invalidity challenge to AbCellera's patent for microfluidic devices and their use in culturing cells
AbCellera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABCL#NASDAQ">ABCL</a>) today announced that the United States Court of Appeals for the Federal Circuit (CAFC) has by a Rule 36 Order affirmed judgment of validity of its U.S. Patent No. 10,087,408 ("the ‘408 Patent"). AbCellera's ‘408 Patent is directed to microfluidic devices and using such devices to culture and selectively recover cells.
Previously Berkeley Lights Inc., now Bruker Cellular Analysis, Inc. (Bruker), a subsidiary of Bruker Corporation, challenged the claims of the ‘408 Patent alleging invalidity based on anticipation and obviousness over the prior art. The U.S. Patent Trial and Appeal Board (PTAB) rejected all of Bruker's arguments and now the CAFC has confirmed that all claims of AbCellera's ‘408 Patent are valid. AbCellera's ‘408 Patent is part of a multi-patent infringement litigation between AbCellera and Bruker pending in the U.S. District Court for the Northern District of California.

ABCL

AbCellera Announces The Federal Circuit Upholds Validity Of Its '408 Patent On Microfluidic Cell-Culturing Devices, Rejecting Bruker Cellular's Invalidity Challenge And Strengthening AbCellera's Position In Ongoing Patent Litigation.

UBS analyst Dan Leonard maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Neutral and lowers the price target from $57 to $45.

UBS Maintains Neutral on Bruker, Lowers Price Target to $45

Barclays analyst Luke Sergott maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Overweight and lowers the price target from $50 to $46.

Barclays Maintains Overweight on Bruker, Lowers Price Target to $46

Goldman Sachs analyst Matthew Sykes maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Neutral and lowers the price target from $50 to $45.

Goldman Sachs Maintains Neutral on Bruker, Lowers Price Target to $45

Stifel analyst Daniel Arias maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Hold and lowers the price target from $57 to $48.

Stifel Maintains Hold on Bruker, Lowers Price Target to $48

Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) lowers FY2025 Adj EPS guidance from $2.67-$2.72 to $2.40-$2.48 vs $2.61 analyst estimate. Raises FY2025 sales outlook from $3.47 billion-$3.54 billion to $3.48 billion-$3.55 billion vs $3.48 billion estimate.

Guidance

Bruker Lowers FY2025 Adj EPS Guidance from $2.67-$2.72 to $2.40-$2.48 vs $2.61 Est; Raises FY2025 Sales Guidance from $3.47B-$3.54B to $3.48B-$3.55B vs $3.48B Est

Press Releases

Bruker Announces Quarterly Dividend

Bruker Introduces Novel MOVE-T System for Transferable, Robust Milk and Liquid Dairy Analysis with FT-NIR Technology

Bruker Launches Novel timsMetabo™ Mass Spectrometer for Breakthrough 4D-Metabolomics and 4D-Lipidomics Sensitivity, Specificity and Annotation Confidence - at Speed, Depth, and Scale

Bruker Launches Revolutionary timsOmniTM Mass Spectrometer

Bruker Corporation to Present at the Jefferies Global Healthcare Conference

Bruker Unveils New proteoElute™ nanoLC System and PepSep® Advanced nLC Columns for up to 50% Improved Peptide Sensitivity

Bruker Launches New timsUltra AIP System with Further Enhanced, Extreme Sensitivity for Single-Cell Proteomics, FNA Biopsy Immunopeptidomics and Metaproteomics

Bruker Announces Acquisition of biocrates, a Leader in Mass Spectrometry-based Quantitative Metabolomics

Bruker Applied MS Unveils Strategic Innovations at ASMS 2025, Showcasing Advances in DART Technology for TDM and DoA Analysis and Launching timsMetabo™ for PFAS and Environmental Contaminant Detection

Bruker Experiences Growth in Semiconductor Advanced Packaging Market Fueled by AI Demands

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Bruker

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL